KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Xenon Pharmaceuticals (XENE) Other Non Operating Income (2016 - 2025)

Xenon Pharmaceuticals (XENE) has disclosed Other Non Operating Income for 13 consecutive years, with -$296000.0 as the latest value for Q4 2025.

  • Quarterly Other Non Operating Income rose 79.97% to -$296000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.3 million through Dec 2025, up 226.69% year-over-year, with the annual reading at $1.3 million for FY2025, 226.69% up from the prior year.
  • Other Non Operating Income for Q4 2025 was -$296000.0 at Xenon Pharmaceuticals, down from -$89000.0 in the prior quarter.
  • The five-year high for Other Non Operating Income was $1.7 million in Q2 2025, with the low at -$2.4 million in Q3 2022.
  • Average Other Non Operating Income over 5 years is -$52500.0, with a median of $76000.0 recorded in 2021.
  • The sharpest move saw Other Non Operating Income plummeted 1760.16% in 2022, then surged 16880.0% in 2025.
  • Over 5 years, Other Non Operating Income stood at $214000.0 in 2021, then soared by 181.31% to $602000.0 in 2022, then crashed by 114.95% to -$90000.0 in 2023, then tumbled by 1542.22% to -$1.5 million in 2024, then skyrocketed by 79.97% to -$296000.0 in 2025.
  • According to Business Quant data, Other Non Operating Income over the past three periods came in at -$296000.0, -$89000.0, and $1.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.